**Pilot implementation of short message service for randomisation in a multisite pragmatic** 

# **Title**



 Author contributions: CO conceived the project, and MC and DK developed the SMS platform. AA and CO supervised the development of the application, The first draft of the manuscript was prepared by MC, and further developed by AA and CO. CN and EL provided clinical trial site supervision. All authors critically reviewed the paper before submission.

## **Abstract**

 The traditional use of sealed envelopes for randomisation is susceptible to manipulation and the risk of damage to envelopes during shipping and at storage. Additionally, the filling and sealing envelopes is, tedious, time-consuming, and error prone. Other randomisation alternatives such as web-based methods are preferred. However, they are expensive and unsuitable in settings with poor internet infrastructure. Mobile phone-based randomisation using Short Message Service (SMS) potentially offers a low-cost and reliable alternative.

 We developed an SMS-based method for random allocation of treatments. Plain text messaging or an Android app were used to formulate text messages using a fixed syntax consisting of participant unique identifier, trial site, stratum, and the trial name as input parameters. The system verified the input parameters and obtained an allocation from the database before returning a response to the sender. The text response contained the details of the treatment allocation. The study was done in two sites of a multi-site 3x2 factorial clinical trial in Kenya involving two interventions with up to nine possible allocations. We evaluated the accuracy of treatment allocations against the master randomisation list for each randomisation SMS processed, and SMS latency in seconds. A post-implementation survey was conducted to evaluate user feedback.

 A total of 218 participants were randomised between 7th February 2022 and 11th April 2022, out of which 179 were randomised to only one arm while 39 were randomised to both treatment arms.

 Allocation accuracy was 100%. Median latency was 22 seconds with the fastest message processed in 10 seconds and the slowest (non-network delayed) message processed in 2129 seconds. Four users completed a post-implementation survey. The pilot study demonstrated that SMS randomisation to be easy, user-friendly, fast, and accurate and a feasible alternative randomisation technique.

## <sup>46</sup> **Author Summary**

47 While conducting a randomized clinical trial with a sample size of more than 4000 participants, in 48 routine care settings in Kenya, we encountered a challenge with the approach to randomisation. In our 49 study protocol we settled on the use of sealed opaque envelopes for allocation concealment. This 50 approach, given our large sample size and nine possible treatment allocations, necessitated the 51 preparation of an overwhelming (4000x9) envelope stratified across 12study sites. This manual process 52 was tedious, time consuming and error prone, with issues arising such as mislabelling, empty 53 envelopes, and some being damaged in storage or transit.

54 Recognizing these challenges, our team was prompted to innovate an alternative digital solution, with 55 the ultimate aim of establishing a proof of concept that could support future clinical trials in routine 56 care settings. Given the high mobile penetration in Kenya, we sought to leverage SMS-based mobile 57 communication as a means of determining treatment allocation for study participants. We developed a 58 platform capable of accommodating both Android and feature phones using open-source tools. Our 59 findings indicate that SMS is a fast, user-friendly, and low-cost method, presenting a viable solution 60 that could potentially revolutionize randomisation in clinical studies. However, it is important to note 61 that our testing of this method was limited to only two study sites. Despite this, our study lays the 62 groundwork for digital randomisation and hopefully inspire future advancements in health research.

3

# **Introduction**



 devices or from a computer to a mobile device. Kenya is reported to have 98% mobile penetration amongst adults(9).

 Bulk messaging enables the synchronous delivery of SMS text messages to a vast number of recipients minimizing delays and overlapping requests. In clinical trials, text messaging has proven effective in reducing missed appointments(10) and has served as a cost-effective intervention for managing patients 90 with chronic illnesses (11–14).

We developed an SMS-based method for random allocation of treatments and subsequently undertook

a pilot study comparing an SMS-based randomisation platform versus the conventional approach using

sealed opaque envelopes. The study was conducted in parallel with a 3x2 factorial pragmatic

randomised controlled trial of alternative treatments for severe pneumonia among children aged 2-59

months(15).

Our aims were to evaluate the feasibility and accuracy of randomisation using text messaging by

estimating the response time of SMS delivery for randomisation requests, assessing the user experience

for envelope randomisation and SMS randomisation approaches, correct treatment allocation, and

determining allocation sequence concordance for envelope randomisation and SMS randomisation.

## **Results**

 Between February 2022 and May 2022, 218 participants were successfully randomised in the two participating clinical trial sites using the SMS approach. One seventy-nine (82.1% - antibiotic arm) participants were randomized in one step and 39 (17.9% - antibiotic & supportive care arm) were randomized in two steps.

 In the testing and pilot phases of the study, we logged a total of 580 SMSes, which we categorized as shown in [Table 1](#page-5-0). We noted various types of SMS requests. For 151 (26%) that fell under the *'invalid non-authorized request*' category, messages consisted of syntax completely unrelated to randomisation, often missing the keyword '*randomize*'. The system reported 22 (4%) requests attempting to randomize participants who were already allocated treatments. One SMS reported under the '*exhausted sequence'* category was a test case scenario where the allocation sequence was no longer available for randomisation. Two unregistered users made attempts to randomise participants, while 402 (69%) requests had valid syntaxes that were processed, and an allocation treatment was delivered to the user

113 as a response.

<b>Text request category</b>	Count	Percentage (%)	
Duplicate attempts	22	$\overline{4}$	
Exhausted sequence	$\mathbf{1}$	0.2	
Invalid non-authorized request	151	26	
Non-authorized valid request	$\overline{2}$	0.3	
Valid successful randomisation	402	69	
Unregistered user	$\overline{2}$	0.3	
<b>Total</b>	580	100	

<span id="page-5-0"></span>**Table 1: Total SMSes processed during the testing and piloting phases of the study.**

The SMS latency for the valid successful randomisation processed requests are as shown in [Table 2](#page-6-0). The median latency was 22 seconds, with the fastest processed SMS taking just 10 seconds (IQR 29.75 seconds). *We observed one delayed response, which was eventually delivered 35 minutes later.* It stands out as an outlier as majority of the SMSes were processed under 100 seconds.

Latency	<b>Total</b>	Min.	$1st$ Qu.	<b>Median</b>	<b>Mean</b>	$3rd$ $Qu$	Max.
range	<b>SMSes</b>						
Less than	393(98%)	10.00	16.00	21.00	31.65	44.00	96.00
$100$ secs							
All	402	10.00	16.00	22.00	46.05	45.75	2129.00

<span id="page-6-0"></span>**Table 2: SMS latency IQR table for valid successful randomisation requests.**

114

115 Allocation accuracy was 100% when compared to the allocation sequence.

 Four clinicians completed a post-pilot survey. From the responses it took a clinician less than two minutes to compose a randomisation text. Two exclusively used the mobile app for randomisation, while two utilized both feature phones and the app. Generally, the clinicians reported that they found SMS randomisation easy to grasp and use. However, opinions on preference were split; two clinicians favoured envelopes, while two preferred text messaging. The Android application was notably preferred over manual texting for composing the randomisation texts. A recurring challenge was forgetfulness in using text randomisation.

## **Discussion**

 Our research provides unique insights as, to the best of our knowledge, it is the first study investigating a Mobile SMS randomisation approach in a low-income setting within a complex randomized controlled clinical trial. Envelope randomisation, a manual and traditional method, is reliant on the integrity of filling, sealing, transporting and storage of envelopes, highlighting the need for digital alternatives such as SMS. In our pilot study, we found SMS randomisation to be user-friendly, efficient, fast, and accurate. It also addressed significant challenges associated with envelope randomisation, such as the time-consuming process of preparing envelopes and uncertainties related to envelopes being unsealed or damaged. Additionally, it eliminates the needs for paper, printing, and shipping. Given the high mobile penetration and widespread use of SMS messaging (16) with a the low cost of SMS at \$0.0078 per unit, the potential of SMS randomisation is evident. SMS processing through a local network recorded a turnaround time of 22 seconds. This highlights the approach's practical potential in pragmatic trials, ensuring that there are no delays in service delivery within a busy public routine care hospital setting during SMS randomisation. The introduction of the mobile application that automated SMS formulation made randomisation more efficient, and no internet connectivity was needed. Despite the predominance of feature phones in the Kenyan Market(17), our solution demonstrates versatility, proving that mobile applications and feature phones can be seamlessly integrated and used interchangeably for SMS randomisation. This ensures broad accessibility and efficiency across different device types.

#### **Digital randomisation techniques**

 As randomisation is a key determinant of the effectiveness of a clinical trial, trialists need to embrace improved and innovative methodologies that include the use of technology where applicable. Trialists are increasingly exploring digital options for conducting randomised controlled trials to mitigate challenges affecting recruitment in clinical trials(18–20). Digitization stands out in ensuring correct and accurate treatment allocation. This not only helps in maintaining the integrity of the clinical trial but also plays a crucial role in minimizing and scrutinizing potential biases in trial outcomes, thereby enhancing the credibility of the results. Clinical trial monitoring becomes more efficient as trial progress can be readily traced in real-time through a randomisation dashboard integrated into the trial data collection process. This feature is particularly beneficial for adaptive clinical trial designs, where the ability to make data-driven decisions in real-time is paramount(21).

#### **Clinical trials in low-resource settings**

 Mobile-based randomisation can solve a number of clinical trial challenges inherent in low- resource settings such as financial constraints, operational barriers such as remote locations of study sites, and limited human capital (22). Setting up clinical trials with complex designs can be prohibitively expensive in such settings (23). This calls for effective methods of conducting trials that deliver credible results while minimizing cost. Our approach, developed using open-source tools, serves a testament to the feasibility of digitizing clinical trial methods in low resource settings. Representing marginalised populations in health research and innovation is crucial for addressing the significant disease burden in low-income countries in a fair and equitable manner (22,24–26). There is an urgent

 need for investment in solutions that will increased the number of clinical trials conducted in low- income countries (27). As our approach only targets two components of clinical trials – randomisation and trial monitoring – additional research is required to pilot other low-cost tools that could improve the quality of clinical trials in similar contexts.

#### **Limitations and recommendations**

 We acknowledge various limitations to our study. The pilot was done in a restricted context with limited number of users and trial sites. Users were clinicians already involved in the larger randomized controlled trial, which could have influenced their feedback and experience. There may be learning curve or initial hesitations for naïve. Clinicians admitting to often forgetting to send the text request after opening the envelope also highlights a behavioural aspect that could be addressed in future implementations to ensure consistent use of the system. The application logic was informed by a simple randomisation technique and tested in an urban setting in Kenya setting with local SMS service providers. This paper does not extend the discussion to implementation in other countries or in rural Kenya where network connectivity may be unstable. Nonetheless, our findings are promising and recommend conducting pilots in various settings, clinical trial designs, and geographical locations. Future iterations of the SMS-based system could introduce enhancements that optimize reliability and guarantee integrity.

#### **Conclusions**

 The promising results from our pilot indicate that there is potential for wider implementation in large- scale clinical trials. The observed improvements in efficiency, high accuracy, and user acceptance point to the viability of SMS randomisation in clinical research in both low and high resource settings. We

 used open-source tools for the development and testing of the SMS platform, ensuring accessibility for further development and improvements. This lessons from this trial serve as a reference point for future low-cost technology-driven innovations to expand the reach and quality of clinical trials globally.

# **Materials and methods**

We conducted a prospective two-arm pilot study nested within an actively recruiting randomised

controlled trial. This study was conducted in two phases. The development phase (Phase 1) involved

the design specification of the SMS platform, and initial testing in web-based, text messaging and

Android applications. The implementation phase (Phase 2) involved deployment of the application at

two public hospitals in Kenya: Machakos Level 5, and Mama Lucy Kibaki Hospitals, selected

purposively from a pool of 12 clinical trial sites due to their high participant recruitment rates.

## **Phase 1: Development phase**

We designed and developed a three-tier SMS-based randomisation system consisting of data,

application, and presentation interfaces ([Figure 1](#page-10-0)). The requirements of the application were derived

from standard operating procedures for randomisation in the larger clinical trial. Therefore, the logic

was structured to accommodate a multi-step factorial randomisation design involving two interventions

with up to nine possible allocations ([Figure 2](#page-10-1)).

<span id="page-10-0"></span>**Figure 1: SMS platform design framework**. The data tier stored all the system data, the business logic tier processed all the system transactions, and the presentation tier was the point of interaction between the user and the system.

<span id="page-10-1"></span>**Figure 2: Factorial allocation of treatments.** Three antibiotic treatment arms (crystalline penicillin & gentamicin, ceftriaxone, and Intravenous (IV) amoxicillin-clavulanic acid) and two supportive care treatment arms (Nasogastric feeds and IV fluids).

- 203 Each message consisted of a predefined ordered syntax comprising the participant unique identifier,
- 204 trial site, stratum, and trial name. Detailed descriptions of the syntax, message scenarios, and expected
- 205 responses are provided in [Table 3](#page-11-0) and [Table 4.](#page-12-0)

#### <span id="page-11-0"></span>**Table 3: SMS formulation syntax of a randomisation request.**



 $1$  The unique patient identifier primarily assigned to a patient at the public hospital.

## <span id="page-12-0"></span>**Table 4: Various SMS formulation request scenarios and their respective expected responses.**





#### 206

 The application tier verified the input parameters received from the mobile network operator through SMS or HTTP via a Representational State Transfer Application Programming Interface (REST API), obtaining an allocation from the data tier stored on a local database. It then returned a response to the sender through an SMS. The text response contained details of the treatment allocation, participant identifier, and identity of the study staff undertaking randomisation. The system was designed to identify duplicate randomisation attempts using unique patient identifiers (IPNO).

213

214 The randomisation application logged all the SMS processed ([Table 5](#page-14-0)). These included invalid text 215 messages, duplicated attempts to randomise, non-authorized request from users not registered and 216 successfully processed valid randomisation requests. Valid randomisation and allocations were logged



### <span id="page-14-0"></span>**Table 5: SMS requests categories.**







 The mobile application was developed in Java for Android, and the web-based platform was developed using the PHP Laravel framework. The platform integrated with an SMS Application Programming Interface (API) from a local premium rate service provider (PRSP). One local mobile network operator was chosen for piloting due to cost related estimations. The source code for the SMS dashboard and the mobile application of this project is archived on GitHub (28,29). The web-based administrative dashboard is locally hosted on the KEMRI-Wellcome Trust servers following data management procedures outlined in the study protocol. At the time of development of this manuscript, the mobile application had not yet been published on the Google Play Store.

## **Phase 2: Pilot SMS randomisation**

 Four clinical trial clinicians carried out the SMS randomisation pilot, with 2 clinicians stationed at each trial site. All users underwent training on how to use the SMS randomisation prior to piloting. The SMS platform was implemented in two modes: through text messaging on feature phones and

 smartphones using an Android mobile application. SMS randomisation was conducted alongside the traditional method of using envelopes. Each clinician was provided with a tablet computer with SIM card registered to the study. The custom Android application was installed on each of the tablets with each clinician having a separate account with a designated role to randomise participants. All system users were pre-registered in the database.

 A study clinician would first screen patients for eligibility and then proceed to randomise them using sealed envelopes (the primary method) and finally repeat the process using text messaging.

Randomisation requests were submitted in structured text format, either manually typed in the phone's

default text messaging application or formulated automatically by the Android application. Texts from

the Android app included a phone number at the end, while manually typed texts did not.

Randomisation marked the final step in recruitment before a treatment was allocated to a participant.

Treatment allocation and administration was based on the envelope concealment method.

 Patient care was always the priority, ensuring that the study procedures did not delay or interfere with treatment. There was no direct risk to participants from the procedures of this study. If technical issues arose, the clinicians were able to call the user support team at the KEMRI-Wellcome Trust Programme for help. Additionally, weekly review meetings were held to assess progress and address any emerging challenges. A post-implementation survey was used to evaluate user feedback. We built a user feedback into the mobile application, which only became active after the pilot implementation was completed. Each user of the randomisation module completed the questionnaire. The study covered the

 cost of the premium SMS subscription package, ensuring that users did not incur any additional charges.

## **Data analysis**

 The SMS platform logged data for each SMS request made, capturing both the initiation time of the request and the time a response was delivered to the user. This enabled us to calculate a turnaround time, or SMS latency, in seconds for each processed message. We then analysed the data by computing the medians with interquartile ranges (IQRs) for turnaround time in seconds. To better describe the range of SMS requests made, we grouped all requests into 6 distinct categories with each SMS assigned to a group ([Table 5](#page-14-0)). We only computed the SMS latency for valid randomisation requests (group 5 in [Table 5](#page-14-0)). A valid request was defined as by the correct structured syntax with all the input 272 parameters required for randomisation. 273 To determine the validity of an (In-Patient Number) (IPNO), we extracted all IPNOs in each SMS 274 request and compared them against the IPNOs in the clinical trial database. We evaluated the accuracy

 of treatment allocations by comparing SMS request response for treatment allocation with the master randomisation list for each processed message. Survey responses from all the users were reviewed and summarized.

## **Acknowledgments**

This project would not have been possible without the kind of support and help from many individuals.

- We would like to extend our sincere gratitude to the following partner: SEARCH Clinical Trial
- Management Group, Mama Lucy Kibaki Hospital study clinicians, paediatric team, and data clerks,

- Machakos Level 5 Hospital study clinicians, paediatric team, and data clerks, and the KEMRI –
- Wellcome Trust Operations Department.

## **Ethics approval and consent to participate**

- The Kenya Medical Research Institute (KEMRI) Scientific and Ethics Review Unit approved the
- collection of the deidentified data analysed in this study. The study clinicians consented to participate
- in the SMS randomisation pilot and to use their names and email addresses for SMS notification and
- verification purposes.

# **Availability of data and materials**

- The data utilized in this work was generated from the SMS randomisation system. Further access to the
- data and additional system design materials can be sought through a request to KEMRI Wellcome
- Trust Research Programme's Data Governance Committee through email: dgc@kemri-wellcome.org.

## **Competing interests**

The authors declare that they have no competing interests.

## **Funding**

- The research reported was funded through The Global Health Network methodology hub and the
- MRC-NIHR Trials Methodology Research Partnership (TMRP) TMRP reference number GH/182.

## **References**

- 1. Altman DG. A fair trial? BMJ. 1984 Aug 11;289(6441):336–7.
- 2. Dettori J. The random allocation process: two things you need to know. Evid-Based Spine-Care J. 2010 Dec;1(3):7–9.

- 3. Kim J, Shin W. How to Do Random Allocation (Randomization). Clin Orthop Surg. 2014 Mar;6(1):103–9.
- 4. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? The Lancet. 1998 Aug 22;352(9128):609–13.
- 5. Kennedy ADM, Torgerson DJ, Campbell MK, Grant AM. Subversion of allocation concealment in a randomised controlled trial: a historical case study. Trials. 2017 May 2;18(1):204.
- 6. Quaglio G, Dario C, Karapiperis T, delponte L, Mccormack S, Tomson G, et al. Information and communications technologies in low and middle-income countries: survey results on economic development and health (Part I). Health Policy Technol. 2016 Jul 1;
- 7. Aker JC, Mbiti IM. Mobile Phones and Economic Development in Africa. J Econ Perspect. 2010 Sep;24(3):207–32.
- 8. Aranda-Jan CB, Mohutsiwa-Dibe N, Loukanova S. Systematic review on what works, what does not work and why of implementation of mobile health (mHealth) projects in Africa. BMC Public Health. 2014 Feb 21;14(1):188.
- 9. Kharono B, Kaggiah A, Mugo C, Seeh D, Guthrie BL, Moreno M, et al. Mobile technology access and use among youth in Nairobi, Kenya: implications for mobile health intervention design. mHealth. 2022 Jan;8:7–7.
- 10. Junod Perron N, Dao MD, Righini NC, Humair JP, Broers B, Narring F, et al. Text-messaging versus telephone reminders to reduce missed appointments in an academic primary care clinic: a randomized controlled trial. BMC Health Serv Res. 2013 Apr 4;13:125.
- 11. Chen Z wen, Fang L zheng, Chen L ying, Dai H lei. Comparison of an SMS text messaging and phone reminder to improve attendance at a health promotion center: A randomized controlled trial. J Zhejiang Univ Sci B. 2008 Jan;9(1):34–8.
- 12. Finitsis DJ, Pellowski JA, Johnson BT. Text message intervention designs to promote adherence to antiretroviral therapy (ART): a meta-analysis of randomized controlled trials. PloS One. 2014;9(2):e88166.
- 13. Park LG, Howie-Esquivel J, Chung ML, Dracup K. A text messaging intervention to promote medication adherence for patients with coronary heart disease: a randomized controlled trial. Patient Educ Couns. 2014 Feb;94(2):261–8.
- 14. Thakkar J, Kurup R, Laba TL, Santo K, Thiagalingam A, Rodgers A, et al. Mobile Telephone Text Messaging for Medication Adherence in Chronic Disease: A Meta-analysis. JAMA Intern Med. 2016 Mar;176(3):340–9.

- 15. Agweyu A. Supportive Care and Antibiotics for Severe Pneumonia Among Hospitalized Children [Internet]. clinicaltrials.gov; 2020 Nov [cited 2021 Aug 15]. Report No.: NCT04041791. Available from: https://clinicaltrials.gov/ct2/show/NCT04041791
- 16. Sector Statistics Report Q3 2022-2023.pdf [Internet]. [cited 2023 Sep 13]. Available from: https://www.ca.go.ke/sites/default/files/2023-06/Sector%20Statistics%20Report%20Q3%202022- 2023.pdf
- 17. Feature phones still dominate Kenya's handset market in a smartphone age | Business News Africa [Internet]. Financial Fortune Media. 2023 [cited 2023 Sep 13]. Available from: https://www.financialfortunemedia.com/feature-phones-still-dominate-kenyas-handset-market-in-the-smartphone-age/
- 18. Blatch-Jones A, Nuttall J, Bull A, Worswick L, Mullee M, Peveler R, et al. Using digital tools in the recruitment and retention in randomised controlled trials: survey of UK Clinical Trial Units and a qualitative study. Trials. 2020 Dec;21(1):304.
- 19. Mehaffey L. RingCentral. 2021 [cited 2023 Sep 13]. 5 best recruitment strategies for clinical trials. Available from: https://www.ringcentral.com/us/en/blog/5-best-recruitment-strategies-for-clinical-351 trials/
- 20. Raven-Gregg T, Wood F, Shepherd V. Effectiveness of participant recruitment strategies for critical care trials: A systematic review and narrative synthesis. Clin Trials. 2021 Aug;18(4):436– 48.
- 21. Lauffenburger JC, Choudhry NK, Russo M, Glynn RJ, Ventz S, Trippa L. Designing and conducting adaptive trials to evaluate interventions in health services and implementation research: practical considerations. BMJ Med. 2022 Jul;1(1):e000158.
- 22. Alemayehu C, Mitchell G, Nikles J. Barriers for conducting clinical trials in developing countries-a systematic review. Int J Equity Health. 2018 Dec;17(1):37.
- 23. Erber AC, Ewing V, Turner M, Molla M, Murbe G, Enquoselassie F, et al. Setting up a pragmatic clinical trial in a low-resource setting: A qualitative assessment of GoLBeT, a trial of podoconiosis management in Northern Ethiopia. Ramos AN, editor. PLoS Negl Trop Dis. 2021 Jul 28;15(7):e0009582.
- 24. Lang T, Siribaddana S. Clinical Trials Have Gone Global: Is This a Good Thing? PLoS Med. 2012 Jun 12;9(6):e1001228.
- 25. Boutayeb A. The Burden of Communicable and Non-Communicable Diseases in Developing Countries. In: Preedy VR, Watson RR, editors. Handbook of Disease Burdens and Quality of Life Measures [Internet]. New York, NY: Springer New York; 2010 [cited 2023 Sep 13]. p. 531–46. Available from: http://link.springer.com/10.1007/978-0-387-78665-0\_32

- 26. Rottingen JA, Chamas C, Goyal L, Harb H, Lagrada L, Mayosi B. Securing the public good of health research and development for developing countries. Bull World Health Organ. 2012 May 1;90(5):398–400.
- 27. Barriers to Conducting Clinical Trials in Developing Countries PMC [Internet]. [cited 2023 Sep 13]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928677/
- 28. Muoki D. muokid3/prisms\_mobi [Internet]. 2023 [cited 2023 Sep 13]. Available from: https://github.com/muokid3/prisms\_mobi
- 29. Muoki D. muokid3/prisms [Internet]. 2023 [cited 2023 Sep 13]. Available from: https://github.com/muokid3/prisms
- 
- **Supporting information**
- 

### **S1 Fig. SMS platform design framework.**

- The data tier stored all the system data, the business logic tier processed all the system transactions, and
- the presentation tier was the point of interaction between the user and the system.

#### **S2 Fig. Factorial allocation of treatments.**

- Three antibiotic treatment arms (crystalline penicillin & gentamicin, ceftriaxone, and Intravenous (IV)
- amoxicillin-clavulanic acid) and two supportive care treatment arms (Nasogastric feeds and IV fluids).
- **S1 Table. Total SMSes processed during the testing and piloting phases of the study.**
- **S2 Table. SMS latency IQR table for valid successful randomisation requests.**
- **S3 Table. SMS formulation syntax of a randomisation request.**
- **S4 Table. Various SMS formulation request scenarios and their respective expected responses.**
- **S5 Table. SMS requests categories.**



# S1 Fig



# S2 Fig